TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31434809

Group type: EXPERIMENTAL
Intervention: Alirocumab (75 mg every 2 weeks, up to 150 mg every 2 weeks)
Number of subjects: 206

Group type: COMPARATOR
Intervention: Standard of care (SoC; atorvastatin ≥10 mg/day or rosuvastatin ≥5 mg/day)
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Alirocumab
Number of subjects: 206

Group type: COMPARATOR
Intervention: Standard of care (SoC)
Number of subjects: 206
Study: 27235022

Group type: EXPERIMENTAL
Intervention: Paleolithic diet (PD)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Paleolithic diet with supervised exercise (PD-EX)
Number of subjects: 32
Study: 26267590

Group type: EXPERIMENTAL
Intervention: Phenylephrine HCl 10 mg
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Phenylephrine HCl 20 mg
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Phenylephrine HCl 30 mg
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 24331714

Group type: EXPERIMENTAL
Intervention: Early food supplementation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multiple micronutrient supplements (MMS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exclusive breastfeeding (EBF) counseling
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pregnancy interventions and breastfeeding counseling
Number of subjects: 0
Study: 21222064

Group type: EXPERIMENTAL
Intervention: Rosuvastatin (2.5 mg daily)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Pitavastatin (2 mg daily)
Number of subjects: 90
Study: 19695386

Group type: EXPERIMENTAL
Intervention: Intranasal fentanyl spray (INFS) 50 to 200 microg
Number of subjects: 111

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 111
Study: 16533286

Group type: EXPERIMENTAL
Intervention: 7-day-old PCT platelets
Number of subjects: 20

Group type: COMPARATOR
Intervention: Reference (R) platelets
Number of subjects: 20
Study: 15479678

Group type: EXPERIMENTAL
Intervention: PEG 3350 (Transipeg: polyethylene glycol with electrolytes)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Lactulose
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: PEG 3350
Number of subjects: 100
Study: 11903155

Group type: EXPERIMENTAL
Intervention: Teledermatology (store-and-forward)
Number of subjects: 49

Group type: COMPARATOR
Intervention: General practitioner face-to-face diagnoses
Number of subjects: 49
Study: 9626916

Group type: EXPERIMENTAL
Intervention: Orlistat 120 mg three times a day (tid)
Number of subjects: 676

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 676

Group type: EXPERIMENTAL
Intervention: Orlistat (all doses)
Number of subjects: 676
Study: 7946366

Group type: EXPERIMENTAL
Intervention: Forced-air warming
Number of subjects: 20

Group type: COMPARATOR
Intervention: Reflective insulation
Number of subjects: 20
Study: 3299174

Group type: EXPERIMENTAL
Intervention: Weekly nonstress testing (NST)
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: NST plus weekly ultrasound evaluation
Number of subjects: 243

Group type: COMPARATOR
Intervention: Control group (normal patients)
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Electronic monitoring
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Ultrasound plus electronic monitoring
Number of subjects: 243
Study: 29387874

Group type: EXPERIMENTAL
Intervention: ECS + FCS
Number of subjects: 30

Group type: COMPARATOR
Intervention: ECS
Number of subjects: 30
Study: 26522611

Group type: EXPERIMENTAL
Intervention: Time-lapse kinetic monitoring (TLM)
Number of subjects: 235

Group type: COMPARATOR
Intervention: Conventional once‐daily morphologic embryo screening (CS)
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Time-lapse kinetic monitoring (TLM) with blastocyst transfers
Number of subjects: 235

Group type: COMPARATOR
Intervention: Conventional once‐daily morphologic embryo screening (CS) with blastocyst transfers
Number of subjects: 235
Study: 25333730

Group type: EXPERIMENTAL
Intervention: Double-blind placebo-controlled food challenge (DBPCFC) in adults
Number of subjects: 271

Group type: COMPARATOR
Intervention: Hazelnut allergy in children
Number of subjects: 271

Group type: COMPARATOR
Intervention: Birch pollen allergy
Number of subjects: 271

Group type: COMPARATOR
Intervention: Diagnostic parameters
Number of subjects: 271
Study: 22878435

Group type: EXPERIMENTAL
Intervention: Educational videodisc
Number of subjects: 92

Group type: COMPARATOR
Intervention: Standard information (control group)
Number of subjects: 92
Study: 20593350

Group type: EXPERIMENTAL
Intervention: Ultrapure dialysate (UPD)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Conventional dialysate (CD)
Number of subjects: 27
Study: 18781483

Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogen 0.625 mg
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study: 11986538

Group type: EXPERIMENTAL
Intervention: Exercise with adherence facilitation intervention (n=7)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Exercise only group (n=6)
Number of subjects: 13
Study: 9822087

Group type: EXPERIMENTAL
Intervention: Abciximab (bolus plus infusion)
Number of subjects: 4154

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4154

Group type: EXPERIMENTAL
Intervention: Abciximab
Number of subjects: 4154
Study: 7950105

Group type: EXPERIMENTAL
Intervention: 5 mm by 6 mm oval PMMA optic (group I)
Number of subjects: 80

Group type: COMPARATOR
Intervention: 6 mm diameter round PMMA optic (group II)
Number of subjects: 80
Study: 2517111

Group type: EXPERIMENTAL
Intervention: Composite sealant applied after enamel etching using a rubber dam.
Number of subjects: 52

Group type: COMPARATOR
Intervention: Cermet cement sealings applied without enamel etching after cleaning with pumice powder and sodium hypochlorite.
Number of subjects: 52
Study: 790946

Group type: EXPERIMENTAL
Intervention: Continuous high-dose aspirin (ASA) for 14 days
Number of subjects: 8

Group type: COMPARATOR
Intervention: Interrupted high-dose aspirin (ASA) for 14 days
Number of subjects: 8
Study: 31813538

Group type: EXPERIMENTAL
Intervention: Younger RBC units (stored for ≤14 days)
Number of subjects: 1387

Group type: COMPARATOR
Intervention: Older RBC units (stored for ≥20 days)
Number of subjects: 1387
Study: 31587887

Group type: EXPERIMENTAL
Intervention: Laparoscopic modified Nissen fundoplication
Number of subjects: 175

Group type: COMPARATOR
Intervention: Omeprazole 80 mg/d, orally
Number of subjects: 175

Group type: COMPARATOR
Intervention: Observation (no gastroesophageal reflux)
Number of subjects: 175
Study: 28346154

Group type: EXPERIMENTAL
Intervention: Text message intervention (2 text messages outlining individualized bedtime goals daily for 8 weekdays)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (no text message intervention)
Number of subjects: 46
Study: 25724704

Group type: EXPERIMENTAL
Intervention: Integrated care (IC) protocol including multidisciplinary care coordination and patient case management
Number of subjects: 363

Group type: COMPARATOR
Intervention: Usual care (controls)
Number of subjects: 363
Study: 23520977

Group type: COMPARATOR
Intervention: Control group (12 eyes without macular pathology)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Diabetic patients with CSME (21 eyes)
Number of subjects: 33
Study: 20934897

Group type: EXPERIMENTAL
Intervention: HbA(1c)
Number of subjects: 700

Group type: EXPERIMENTAL
Intervention: FPG and HbA(1c) combination
Number of subjects: 700

Group type: COMPARATOR
Intervention: FPG
Number of subjects: 700

Group type: COMPARATOR
Intervention: 2hPG
Number of subjects: 700
Study: 19345768

Group type: EXPERIMENTAL
Intervention: Kinesthetic motor imagery of finger flexion movements during the postoperative dynamic splinting period
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (no motor imagery)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Motor imagery group
Number of subjects: 28
Study: 16689755

Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg day(-1)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg day(-1)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Fenofibrate 160 mg day(-1)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Quinapril 10 mg day(-1)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Aspirin 75 mg day(-1)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: All drugs tested (including aspirin)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: All groups post-treatment
Number of subjects: 48
Study: 15558071

Group type: EXPERIMENTAL
Intervention: Weekly docetaxel (33.3 mg m(‐2) for 6 weeks)
Number of subjects: 220

Group type: COMPARATOR
Intervention: 3-weekly docetaxel (75 mg m(‐2))
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Both weekly and 3-weekly docetaxel
Number of subjects: 220
Study: 11780943

Group type: EXPERIMENTAL
Intervention: Right prefrontal rTMS (N = 16)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Left prefrontal rTMS (N = 15)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Sham rTMS (N = 15)
Number of subjects: 46
Study: 9436162

Group type: EXPERIMENTAL
Intervention: Behavioral strategies for managing auditory hallucinations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Group practice of behavioral strategies
Number of subjects: 0
Study: 8493629

Group type: EXPERIMENTAL
Intervention: Salmeterol (50 micrograms twice daily)
Number of subjects: 388

Group type: COMPARATOR
Intervention: Salbutamol (400 micrograms four times daily)
Number of subjects: 388

Group type: COMPARATOR
Intervention: Salbutamol (400 micrograms twice daily)
Number of subjects: 388

Group type: EXPERIMENTAL
Intervention: Salmeterol and Salbutamol
Number of subjects: 388
Study: 30636064

Group type: EXPERIMENTAL
Intervention: Four implants in the posterior maxilla
Number of subjects: 66

Group type: COMPARATOR
Intervention: Six implants in the posterior maxilla
Number of subjects: 66
Study: 28560762

Group type: EXPERIMENTAL
Intervention: Desmopressin 25 µg ODT + Tolterodine 4 mg (n=49)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Tolterodine 4 mg (n=57)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Desmopressin + Tolterodine (n=49)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Tolterodine (n=57)
Number of subjects: 106
Study: 27596569

Group type: EXPERIMENTAL
Intervention: Smartphone-based secondary prevention program emphasizing early physical activity with a graduated walking program initiated on discharge from ACS admission.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Smartphone-based secondary prevention program
Number of subjects: 0
Study: 25362163

Group type: EXPERIMENTAL
Intervention: Metoprolol administration
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Simulated RR series with metoprolol
Number of subjects: 60
Study: 23043031

Group type: EXPERIMENTAL
Intervention: Sparrow-SES
Number of subjects: 36

Group type: COMPARATOR
Intervention: Cypher-SES
Number of subjects: 36
Study: 20449538

Group type: EXPERIMENTAL
Intervention: Telmisartan (80 mg/day)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Olmesartan (40 mg/day)
Number of subjects: 65
Study: 18319519

Group type: EXPERIMENTAL
Intervention: Facilitated PCI (tenecteplase)
Number of subjects: 1090

Group type: COMPARATOR
Intervention: Primary PCI
Number of subjects: 1090

Group type: EXPERIMENTAL
Intervention: Facilitated PCI
Number of subjects: 1090

Group type: EXPERIMENTAL
Intervention: No baseline Q waves
Number of subjects: 1090
Study: 16482400

Group type: EXPERIMENTAL
Intervention: BCNU wafers
Number of subjects: 240

Group type: COMPARATOR
Intervention: Placebo wafers
Number of subjects: 240
Study: 14738209

Group type: EXPERIMENTAL
Intervention: Concentrated ambient particles (CAPs) (n = 30)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Filtered air (n = 8)
Number of subjects: 38
Study: 11123825

Group type: EXPERIMENTAL
Intervention: Ivermectin (400 microg/kg/body weight)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Diethyl carbamazine (DEC) (6 mg/kg/body weight)
Number of subjects: 30
Study: 9186324

Group type: EXPERIMENTAL
Intervention: Transurethral resection alone or combined with intravesical bacillus Calmette‐Guerin
Number of subjects: 86

Group type: COMPARATOR
Intervention: Control group (Transurethral resection alone)
Number of subjects: 86
Study: 8259846

Group type: EXPERIMENTAL
Intervention: Ftorafur (FT) 600 mg/day for 2 years
Number of subjects: 647

Group type: EXPERIMENTAL
Intervention: Ftorafur (FT) 600 mg/day plus Tamoxifen (TAM) 20 mg/day for 2 years
Number of subjects: 647

Group type: COMPARATOR
Intervention: Tamoxifen (TAM) 20 mg/day for 2 years
Number of subjects: 647
Study: 3964494

Group type: EXPERIMENTAL
Intervention: Phosphate (1.5 g/day)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Calcitonin (50 IU X 5 days every third week)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Combined therapy (Phosphate + Calcitonin)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Double placebos
Number of subjects: 44
Study: 30848494

Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 29239867

Group type: EXPERIMENTAL
Intervention: AZI/AML/HCTZ 20/5/12.5 mg
Number of subjects: 353

Group type: EXPERIMENTAL
Intervention: AZI/AML/HCTZ 20/5/6.25 mg
Number of subjects: 353

Group type: EXPERIMENTAL
Intervention: AZI/AML 20/5 mg
Number of subjects: 353

Group type: COMPARATOR
Intervention: HCTZ 12.5 mg
Number of subjects: 353

Group type: COMPARATOR
Intervention: HCTZ 6.25 mg
Number of subjects: 353

Group type: EXPERIMENTAL
Intervention: Home BP measurement
Number of subjects: 353

Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 353
Study: 27233494

Group type: EXPERIMENTAL
Intervention: PeriopSim™ Instrument Trainer
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: PeriopSim™ for Burr Hole Surgery
Number of subjects: 18
Study: 25549485

Group type: EXPERIMENTAL
Intervention: High-doses of antithrombin III (AT)
Number of subjects: 29

Group type: COMPARATOR
Intervention: No antithrombin III (AT)
Number of subjects: 29
Study: 22470133

Group type: EXPERIMENTAL
Intervention: Interdisciplinary care model
Number of subjects: 189
Study: 20099274

Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy (IPT) focused on grief
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy (IPT) focused on role transitions
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy (IPT) focused on role disputes
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy (IPT) focused on interpersonal deficits
Number of subjects: 182
Study: 17275553

Group type: EXPERIMENTAL
Intervention: Dexamethasone 4 mg
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Dexamethasone 8 mg
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 16088081

Group type: EXPERIMENTAL
Intervention: Ferumoxytol at 1 mg iron/kg
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Ferumoxytol at 2 mg iron/kg
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Ferumoxytol at 4 mg iron/kg
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Ferumoxytol at 4 mg iron/kg at injection rates of 90 mg/min
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Ferumoxytol at 4 mg iron/kg at injection rates of 180 mg/min
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Ferumoxytol at 4 mg iron/kg at injection rates of 1800 mg/min
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Ferumoxytol at 125 mg over 5 min in hemodialysis patients
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Ferumoxytol at 250 mg over 5 min in hemodialysis patients
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Ferumoxytol in both populations
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 12390947

Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 2289

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2289
Study: 11757538

Group type: EXPERIMENTAL
Intervention: Biliary stones < or = 3 mm in diameter recovered in patients with ductal stones (n=22).
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (17 patients) with normal antegrade SO activity.
Number of subjects: 39
Study: 7749431

Group type: EXPERIMENTAL
Intervention: Long protocol of gonadotropin releasing hormone agonist (GnRH‐a) administration
Number of subjects: 90

Group type: COMPARATOR
Intervention: Short protocol of gonadotropin releasing hormone agonist (GnRH‐a) administration
Number of subjects: 90
Study: 2108634

Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 12

Group type: COMPARATOR
Intervention: Double placebo
Number of subjects: 12
Study: 575498

Group type: EXPERIMENTAL
Intervention: Creatinol O-phosphate (COP) 3.06 g i.v./24 h for 3 days
Number of subjects: 46

Group type: COMPARATOR
Intervention: Glucose-insulin-K+ (GIK) for 3 days
Number of subjects: 46
Study: 31484799

Group type: EXPERIMENTAL
Intervention: Selling tobacco
Number of subjects: 4527

Group type: EXPERIMENTAL
Intervention: Formerly selling tobacco
Number of subjects: 4527

Group type: EXPERIMENTAL
Intervention: Stopped selling tobacco
Number of subjects: 4527

Group type: EXPERIMENTAL
Intervention: Might stop selling tobacco
Number of subjects: 4527

Group type: EXPERIMENTAL
Intervention: Current sellers unlikely to stop selling
Number of subjects: 4527

Group type: EXPERIMENTAL
Intervention: Former tobacco retailers in Western Australia
Number of subjects: 4527
Study: 30856652

Group type: EXPERIMENTAL
Intervention: Total thyroidectomy
Number of subjects: 150

Group type: COMPARATOR
Intervention: Medical management
Number of subjects: 150
Study: 28303156

Group type: EXPERIMENTAL
Intervention: Acu-TENS
Number of subjects: 21

Group type: COMPARATOR
Intervention: Sham-TENS
Number of subjects: 21

Group type: COMPARATOR
Intervention: Acu-TENS and Sham-TENS
Number of subjects: 21
Study: 25556916

Group type: EXPERIMENTAL
Intervention: Paclitaxel/carboplatin plus sorafenib (400 mg orally twice daily)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Paclitaxel/carboplatin
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Paclitaxel/carboplatin plus sorafenib
Number of subjects: 85
Study: 23363643

Group type: EXPERIMENTAL
Intervention: Prasugrel 30 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Clopidogrel 600 mg
Number of subjects: 12
Study: 20350786

Group type: EXPERIMENTAL
Intervention: Neoadjuvant androgen deprivation therapy (NADT) for 0, 3, or 6 months prior to and during radiation treatment at 66 Gy
Number of subjects: 802

Group type: COMPARATOR
Intervention: Radiation treatment alone
Number of subjects: 802

Group type: EXPERIMENTAL
Intervention: Neoadjuvant androgen deprivation therapy (NADT)
Number of subjects: 802
Study: 19476583

Group type: EXPERIMENTAL
Intervention: Screening lipid profiles
Number of subjects: 5031

Group type: EXPERIMENTAL
Intervention: Appropriate management within 4 months after screening
Number of subjects: 5031

Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 5031

Group type: EXPERIMENTAL
Intervention: LDL cholesterol <or=130 mg/dL
Number of subjects: 5031

Group type: EXPERIMENTAL
Intervention: Low-risk group
Number of subjects: 5031

Group type: EXPERIMENTAL
Intervention: LDL levels between 131 and 159 mg/dL
Number of subjects: 5031

Group type: EXPERIMENTAL
Intervention: Risk category
Number of subjects: 5031
Study: 17295586

Group type: EXPERIMENTAL
Intervention: Flatline cluster smoking patterns
Number of subjects: 351

Group type: EXPERIMENTAL
Intervention: Daily dip-evening incline cluster smoking patterns
Number of subjects: 351

Group type: EXPERIMENTAL
Intervention: Morning high cluster smoking patterns
Number of subjects: 351

Group type: EXPERIMENTAL
Intervention: Daily decline cluster smoking patterns
Number of subjects: 351
Study: 12891637

Group type: EXPERIMENTAL
Intervention: Long-acting opioid therapy for 4 weeks
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo for 4 weeks
Number of subjects: 47
Study: 10861152

Group type: EXPERIMENTAL
Intervention: ProSeal laryngeal mask airway (PLMA)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard laryngeal mask airway (LMA)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: ProSeal laryngeal mask airway (PLMA) with introducer
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: ProSeal laryngeal mask airway (PLMA) without introducer
Number of subjects: 60
Study: 9198464

Group type: EXPERIMENTAL
Intervention: aceclofenac 100 mg/12 h
Number of subjects: 30

Group type: COMPARATOR
Intervention: paracetamol 650 mg/12 h
Number of subjects: 30
Study: 1439622

Group type: EXPERIMENTAL
Intervention: Arthrotec (50 mg diclofenac + 200 micrograms misoprostol)
Number of subjects: 1501

Group type: COMPARATOR
Intervention: Diclofenac (50 mg)
Number of subjects: 1501
Study: 3084266

Group type: EXPERIMENTAL
Intervention: Clindamycin
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Ampicillin
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Metronidazole
Number of subjects: 18
Study: 31678224

Group type: EXPERIMENTAL
Intervention: Local consolidative therapy (LCT)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Baseline interleukin 1α
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Serial ctDNA analysis
Number of subjects: 49
Study: 31369355

Group type: EXPERIMENTAL
Intervention: Integrated Behavioral Model (IBM)‐based 3‐month transitional care (TC) intervention
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 60
Study: 24858257

Group type: EXPERIMENTAL
Intervention: Combination of Chinese medicine (CM) and Western medicine intervention termed optimum proposal of integration of disease and syndrome (OPIDS)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Conventional Western medicine
Number of subjects: 126
Study: 23470610

Group type: EXPERIMENTAL
Intervention: Amisulpride with ECT
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (ECT without amisulpride)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Study group (Amisulpride with ECT)
Number of subjects: 20
Study: 21319927

Group type: EXPERIMENTAL
Intervention: Safety behavior reduction plus exposure (SB + EXP)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Graduated exposure (EXP)
Number of subjects: 80